The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
November 21st 2024
Investigators also established a negative association with higher vitamin C intake and diabetes prevalence.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered ...
1.5 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Barriers in Integrated Continuous Glucose Monitoring Use, Featuring Patient Counseling Video Vignette...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Integrated Continuous Glucose Monitoring: What’s New in 2024, Featuring a Device Demonstration and Patient Cou...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Strategies for Addressing Cardiovascular Disease, Diabetes, and Chronic Kidney Disease With SGLT2 Inhibitors
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Reducing Endocrinopathies of Immune Checkpoint Inhibitor Therapy: Management Strategies for Oncology Pharmacis...
1.0 Credit / Oncology, Endocrinology, Diabetes & Metabolism
View More
Foundations in Continuous Glucose Monitoring
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
SimulatED: Using Continuous Glucose Monitoring Data to Improve Health Outcomes (Pharmacy Technician Credit)
0.75 Credit / Endocrinology, Diabetes & Metabolism
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Uncovering the Challenges in Treatment Pathways in AMD and DME
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Navigating Anti-Vascular Endothelial Growth Factor Therapy and Dosing Strategies
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Improving Patient Outcomes in AMD and DME Through the Integration of Specialty Pharmacy Care
1.0 Credit / Endocrinology, Diabetes & Metabolism, Ophthalmology & Optometry
View More
Best Practices for the Integration of Continuous Glucose Monitoring Within the Health System
1.5 Credits / Endocrinology, Diabetes & Metabolism
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Best Practices for the Integration of Continuous Glucose Monitoring Devices Across Community Pharmacy Settings
1.5 Credits / Endocrinology, Diabetes & Metabolism
View More
The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outc...
1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
View More
Innovations in Diabetes Technology: A New Era of Patient Choice and Opportunities for Pharmacists to Support I...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
Innovations in Diabetes Technology: A New Era of Patient Choice and Opportunities for Pharmacists to Support I...
1.0 Credit / Endocrinology, Diabetes & Metabolism
View More
FDA Delays Approval Decision for Sanofi's Insulin Glargine, Lixisenatide Pen for Diabetes
September 1st 2016Sanofi has submitted updated information to the FDA as part of a previously submitted New Drug Application (NDA) for its investigational once-daily, fixed-ratio combination of basal insulin glargine 100 units/mL (Lantus) and lixisenatide (Adlyxin) to treat type 2 diabetes in adults.
Read More